CN102027007A - 长效的y2和/或y4受体激动剂 - Google Patents

长效的y2和/或y4受体激动剂 Download PDF

Info

Publication number
CN102027007A
CN102027007A CN2009801173043A CN200980117304A CN102027007A CN 102027007 A CN102027007 A CN 102027007A CN 2009801173043 A CN2009801173043 A CN 2009801173043A CN 200980117304 A CN200980117304 A CN 200980117304A CN 102027007 A CN102027007 A CN 102027007A
Authority
CN
China
Prior art keywords
ethoxy
xaa
seq
acid
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN2009801173043A
Other languages
English (en)
Chinese (zh)
Inventor
S·奥斯特加尔德
S·M·克努德森
J·斯佩茨勒
R·约根森
J·科福德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN102027007A publication Critical patent/CN102027007A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801173043A 2008-05-16 2009-05-18 长效的y2和/或y4受体激动剂 Withdrawn CN102027007A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08156360.3 2008-05-16
EP08156360 2008-05-16
EP09154461.9 2009-03-05
EP09154461 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (1)

Publication Number Publication Date
CN102027007A true CN102027007A (zh) 2011-04-20

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801173043A Withdrawn CN102027007A (zh) 2008-05-16 2009-05-18 长效的y2和/或y4受体激动剂

Country Status (12)

Country Link
US (1) US20110275559A1 (https=)
EP (1) EP2279204A1 (https=)
JP (1) JP2011520847A (https=)
KR (1) KR20110017874A (https=)
CN (1) CN102027007A (https=)
AU (1) AU2009248041B2 (https=)
BR (1) BRPI0912615A2 (https=)
CA (1) CA2723855A1 (https=)
IL (1) IL208836A0 (https=)
MX (1) MX2010011845A (https=)
RU (1) RU2504550C2 (https=)
WO (1) WO2009138511A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764919A (zh) * 2013-11-15 2016-07-13 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
CN107849110A (zh) * 2015-06-12 2018-03-27 诺和诺德股份有限公司 选择性pyy化合物及其用途
CN114269774A (zh) * 2019-06-12 2022-04-01 Ip2Ipo创新有限公司 食欲抑制化合物
TWI914344B (zh) 2020-04-17 2026-02-11 美商Ｉ２Ｏ醫療股份有限公司 長效酪酪肽(pyy)類似物及使用方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US8927687B2 (en) 2010-07-09 2015-01-06 Amylin Pharmaceuticals, Llc Microcrystalline Y receptor agonists
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
PT3068421T (pt) * 2013-11-15 2019-07-11 Novo Nordisk As Compostos de pyy eletivo e usos dos mesmos
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
CA2949535C (en) * 2014-05-21 2023-09-12 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
IL297368A (en) * 2020-04-17 2022-12-01 I2O Therapeutics Inc Long-acting peptide tyrosine kinase (pyy) analogs and methods of use
CA3215858A1 (en) 2021-04-27 2022-11-03 Zhenhuan ZHENG Combination of bitter receptor agonist and gut-signaling compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027978A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005089786A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027978A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005089786A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105764919A (zh) * 2013-11-15 2016-07-13 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
CN107849110A (zh) * 2015-06-12 2018-03-27 诺和诺德股份有限公司 选择性pyy化合物及其用途
CN107849110B (zh) * 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
CN114269774A (zh) * 2019-06-12 2022-04-01 Ip2Ipo创新有限公司 食欲抑制化合物
TWI914344B (zh) 2020-04-17 2026-02-11 美商Ｉ２Ｏ醫療股份有限公司 長效酪酪肽(pyy)類似物及使用方法

Also Published As

Publication number Publication date
MX2010011845A (es) 2010-11-22
WO2009138511A1 (en) 2009-11-19
BRPI0912615A2 (pt) 2016-01-26
KR20110017874A (ko) 2011-02-22
AU2009248041B2 (en) 2013-10-03
JP2011520847A (ja) 2011-07-21
US20110275559A1 (en) 2011-11-10
EP2279204A1 (en) 2011-02-02
AU2009248041A1 (en) 2009-11-19
CA2723855A1 (en) 2009-11-19
RU2504550C2 (ru) 2014-01-20
IL208836A0 (en) 2011-01-31
RU2010149474A (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
CN102027007A (zh) 长效的y2和/或y4受体激动剂
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
JP5476304B2 (ja) グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
CN102918055B (zh) 新的胰高血糖素类似物
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
US20130040877A1 (en) Long-acting y2 receptor agonists
JP2013510829A (ja) 長時間作用型ｙ２受容体アゴニスト
WO2009030771A1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物
KR20110110174A (ko) 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
JP2023528921A (ja) Ｇｌｐ１ｒアゴニスト・ｎｍｄａｒアンタゴニストコンジュゲート
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
KR20260010743A (ko) 경구 전달용 폴리펩티드 유도체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20110420